Premedication to Mitigate Amivantamab Infusion Related Reactions
Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
The purpose of the study is to separately assess the potential of dexamethasone, montelukast
and methotrexate, administration, prior to amivantamab infusion given through a needle in the
vein, to decrease the incidence and/or severity of infusion related reaction (IRR), when
amivantamab is given in combination with Lazertinib (by mouth), to reduce first-dose IRRs.